Extended Data Fig. 6: Kaplan-Meier estimates of survival by SETD2 mutational status. | Nature Medicine

Extended Data Fig. 6: Kaplan-Meier estimates of survival by SETD2 mutational status.

From: Pembrolizumab plus axitinib versus sunitinib for advanced clear cell renal cell carcinoma: 5-year survival and biomarker analyses of the phase 3 KEYNOTE-426 trial

Extended Data Fig. 6

a, Overall survival. b, Progression-free survival. HR was estimated using the Cox proportional hazards model, with adjustment for IMDC risk category. HR, hazard ratio; IMDC, International Metastatic Renal Cell Carcinoma Database Consortium; OS, overall survival; PFS, progression-free survival; SETD2, SET domain containing 2, histone lysine methyltransferase gene; WT, wild type.

Back to article page